Oral semaglutide cuts heart failure events in SOUL secondary analysis

The wire

1. 01A secondary analysis of the SOUL trial, published in JAMA Internal Medicine, followed nearly 9,650 adults with Type 2 diabetes plus cardiovascular or chronic kidney disease for nearly four years.
2. 02Benefit was most notable in heart failure with preserved ejection fraction, and senior author Rodica Pop-Busui said the oral formulation was safe in this group, countering prior safety concerns.
3. 03No significant reduction in heart failure events was seen in participants without prior heart failure, and the findings come from a secondary, not prespecified primary, analysis.

From the source

Oral semaglutide lowers risk of heart failure events in people with Type 2 diabetes

An international clinical trial has found that an oral form of semaglutide, a widely used diabetes drug, reduced the risk of serious heart failure events in people with Type 2 diabetes who already had heart failure.